# Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

Study · id `cardio:ct-nct04273945` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04273945](<https://clinicaltrials.gov/study/NCT04273945>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT04273945

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 935 participants.

## Technical summary

Registry record NCT04273945. Randomized; triple masking; primary purpose treatment. Start 2020-06-30 (actual); primary completion 2025-10-07 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 935 participants (enrolled count; ClinicalTrials.gov record NCT04273945, source copy `cardio:ctgov-nct04273945-2026-11-03`, retrieved 2026-11-18)
- Started: 2020-06-30 (actual) (ClinicalTrials.gov record NCT04273945, source copy `cardio:ctgov-nct04273945-2026-11-03`, retrieved 2026-11-18)
- Primary completion: 2025-10-07 (actual) (ClinicalTrials.gov record NCT04273945, source copy `cardio:ctgov-nct04273945-2026-11-03`, retrieved 2026-11-18)
- Completion: 2029-02-20 (anticipated) (ClinicalTrials.gov record NCT04273945, source copy `cardio:ctgov-nct04273945-2026-11-03`, retrieved 2026-11-18)
- Countries: United States; Argentina; Australia; Austria; Belarus; Belgium; Brazil; Bulgaria; Canada; China; Colombia; Czechia; Denmark; France; Germany; Greece; Hungary; India; Israel; Italy; Japan; Malaysia; Mexico; Netherlands; Norway; Poland; Portugal; Russia; Saudi Arabia; Serbia; Singapore; Slovakia; South Africa; South Korea; Spain; Sweden; Taiwan; Thailand; Türkiye; Ukraine; United Kingdom; Vietnam (ClinicalTrials.gov record NCT04273945, source copy `cardio:ctgov-nct04273945-2026-11-03`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04273945-2026-11-03`, retrieved 2026-11-18)

## The registry's words

- Brief title: Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension
- Acronym: UNISUS
- Condition: Pulmonary Arterial Hypertension
- Intervention (Drug): Macitentan 10 mg
- Intervention (Drug): Macitentan 37.5 mg
- Intervention (Drug): Macitentan 75 mg
- Intervention (Drug): Placebo
- Lead sponsor: Actelion
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`)
- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry lists this organization as the lead sponsor: Actelion (`cardio:org-actelion`)

## Provenance

Content hash: e61a0d2277800ba7625e11d7023e1a65bb2b86b32997e0a5c8130c6e3558d666
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
